ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1786

Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury

Sladjana Skopelja-Gardner1, Xizhang Sun 2, Yufeng Peng 2, Lucrezia Colonna 2, Payton Hermanson 2, Lena Tanaka 2, Joyce Tai 2, David Salant 3 and Keith Elkon 2, 1University of Washington, Seattle, WA, 2University of Washington, Seattle, 3Boston University, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus, lupus nephritis and complement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M094: SLE – Animal Models (1782–1787)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Lupus nephritis (LN) is a major contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Defective clearance of apoptotic cells (AC), autoantibodies, and low complement levels are three hallmarks of SLE pathogenesis that have not yet been captured in a single disease model.  We posit that such a model will allow us to elucidate the clinically relevant mechanisms of kidney injury in SLE and shed light on the multifaceted role of complement in this disease.  

Methods: To investigate mechanisms of kidney injury in a disease model that mimics the polygenic nature of human SLE, we generated C57BL/6 mice that produced anti-chromatin antibodies (Sle1), had defective clearance of AC (Mfge8-/-) and were deficient in either C1q [C1q Triple mutant (C1qTM)] or C3 (C3TM). Kidney injury was evaluated by urine albumin/creatinine ratio (UACR), PAS staining, immunofluorescence (IF) staining and electron microscopy (EM). The effect of thrombin inhibition with argatroban on kidney injury in Mfge8-/-C3-/- (C3 double mutant, DM) mice was studied in the nephrotoxic-nephritis (NTN) model of kidney injury.

Results: C1qTM and C3TM mice, but not any double mutant controls, developed spontaneous membranoproliferative glomerulonephritis (MPGN) with PAS positive deposits, glomerular hypercellularity and variable mesangial and endocapillary proliferation at ~10 months of age. EM revealed features reminiscent of human LN: “wire loop” and glomerular mesangial immune deposits in fibrillary organized structures. MPGN in C1qTM and C3TM mice was accompanied by increased glomerular deposition of IgG and AC. At 5 months of age, C1qTM and C3TM mice spontaneously developed high anti-dsDNA and anti-chromatin IgG titers as well as marked antigen spreading, including antigens previously implicated in LN pathogenesis.    

                  Remarkably, IF staining revealed membrane attack complex (MAC) deposition in both TM strains. In C1qTM mice MAC deposition was associated with glomerular deposition of C3/C3d. Terminal complement activation in C3TM kidneys was accompanied by increased glomerular deposition of the thrombin substrate, fibrin. We also observed increased thrombin enzymatic activity in the plasma of C3TM mice, relative to C1qTM controls. Using the NTN model of kidney injury in Mfge8-/-C3-/- mice, the thrombin inhibitor, argatroban, significantly reduced glomerular MAC deposition and UACR, compared to vehicle treated controls.

Conclusion: In the context of reduced clearance of AC (Mfge8-/-) and non-pathogenic autoantibodies (Sle1), early complement component deficiencies (C1q or C3) have two distinct effects: i) their absence leads to B cell activation and epitope spreading and ii) surrogate pathways allow terminal complement MAC activation. In C1qTM mice, increased glomerular C3/C3d deposition suggests activation of the lectin or alternative complement pathways, in the absence of C1q. Increased fibrin deposition in C3TM and rescue of proteinuria in NTN C3DM mice by a thrombin inhibitor, suggest that thrombin acts as a C5 convertase in low C3 states. These data encourage surrogate pathway evaluation in SLE patients with low complement states and offer new potential targets for therapy.


Disclosure: S. Skopelja-Gardner, None; X. Sun, None; Y. Peng, None; L. Colonna, None; P. Hermanson, None; L. Tanaka, None; J. Tai, None; D. Salant, None; K. Elkon, None.

To cite this abstract in AMA style:

Skopelja-Gardner S, Sun X, Peng Y, Colonna L, Hermanson P, Tanaka L, Tai J, Salant D, Elkon K. Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/surrogate-pathways-of-complement-activation-in-novel-polygenic-sle-like-models-of-kidney-injury/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/surrogate-pathways-of-complement-activation-in-novel-polygenic-sle-like-models-of-kidney-injury/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology